News

Public · Published

CYTK: MYQORZO momentum grew as aficamten advanced toward an nHCM filing

MYQORZO revenue reached $44.5M, up 76% from the previous quarter, as U.S. prescribing expanded and European launches began. Cytokinetics said aficamten's supplemental application for non-obstructive hypertrophic cardiomyopathy is on track for filing in the fourth quarter of 2026, while pipeline programs advanced.

Published:

Updated:

What happened

MYQORZO revenue reached $44.5M, up 76% from the previous quarter, as U.S. prescribing expanded and European launches began. Cytokinetics said aficamten’s supplemental application for non-obstructive hypertrophic cardiomyopathy is on track for filing in the fourth quarter of 2026, while pipeline programs advanced.

Confirmed

Global impact / market context

Higher MYQORZO sales could increase Cytokinetics’ revenue if prescribing and European launches continue to grow. Aficamten’s planned filing creates a potential future route to broaden the company’s product sales, but the timing and commercial contribution depend on completing the filing and subsequent progress.

Analyst inference

The supplied update gives a recent sales-growth figure alongside a future filing target, but no profit, cash available, or spending information. Investors therefore have evidence of rising product revenue, while the financial cost and eventual value of advancing aficamten remain unclear.

Analyst inference

What to watch

  1. Check whether MYQORZO revenue growth continues in later updates, since sustained U.S. prescribing and European launches would support continued sales expansion. Analyst inference
  2. Watch for confirmation that aficamten’s supplemental application is filed in the fourth quarter of 2026, the timing currently described as on track. Confirmed
  3. Look for later details on pipeline progress and spending, which could show whether development adds costs before aficamten or other programs generate revenue. Analyst inference

Evidence

  • Original source link unavailable